Takeda Pharmaceutical (TAK) Gains from Sales and Divestitures (2018 - 2025)

Takeda Pharmaceutical has reported Gains from Sales and Divestitures for 5 years, with the latest figure at $1.5 billion in Q3 2025.

• On a quarterly basis, Gains from Sales and Divestitures changed N/A year-over-year to $1.5 billion in Q3 2025; TTM through Sep 2025 was $6.3 billion, a N/A change from a year earlier, with the FY2021 full-year figure at -$19.9 million, down 118.42% from the prior year.
• Gains from Sales and Divestitures was $1.5 billion for Q3 2025 at Takeda Pharmaceutical, down from $2.0 billion in the prior quarter.
• The five-year high for Gains from Sales and Divestitures was $2.1 billion in Q3 2022, with the low at $793.8 million in Q1 2023.
• Average Gains from Sales and Divestitures over 3 years is $1.6 billion, with a median of $1.7 billion recorded in 2023.
• The largest YoY upside for Gains from Sales and Divestitures was 4.37% in 2023 against a maximum downside of 4.37% in 2023.
• Over 3 years, Gains from Sales and Divestitures stood at $2.1 billion in 2022, then retreated by 4.37% to $2.0 billion in 2023, then retreated by 25.85% to $1.5 billion in 2025.
• The last three Gains from Sales and Divestitures figures came in at $1.5 billion (Q3 2025), $2.0 billion (Q3 2023), and $793.8 million (Q1 2023), per Business Quant data.